Table 2 Chemotherapy and disease response characteristics

From: Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data

    Kang et al (2012)
Chemotherapy details Ford et al (2014) n (%) Thuss-Patience et al (2011) n (%) Total, n (%) Docetaxel arm, n (%) Irinotecan arm, n (%)
CT+SC 84 21 133 70 63
CT type
Docetaxel 84 (100%) 0 70 (51%)   
Irinotecan 0 21 (100%) 63 (47%)   
Number of cycles administered
0 7 (8%) 2 (10%) 2 (2%) 1 (1%) 1 (2%)
1 17 (20%) 2 (10%) 20 (15%) 11 (16%) 9 (14%)
2 10 (12%) 7 (33%) 29 (22%) 20 (29%) 9 (14%)
3 23 (27%) 2 (10%) 23 (17%) 13 (19%) 10 (16%)
4 5 (6%) 2 (10%) 10 (8%) 4 (6%) 6 (10%)
5 3 (4%) 3 (14%) 6 (5%) 1 (1%) 5 (8%)
6 19 (23%) 1 (5%) 22 (17%) 13 (19%) 9 (14%)
>6 0 2 (10%) 21 (16%) 7 (10%) 14 (22%)
Total number of cycles 255 68 543 243 300
Median number of cycles (range) 3 (0–6) 2 (0–9) 3 (0–12) 3 (0–9) 4 (0–12)
Reason for treatment ending
Completion of treatment 19 (23%) 0 0 0 0
Unacceptable toxicity 20 (24%) 2 (10%) 2 (1%) 2 (3%) 0
Treatment delay >21 days 5 (6%) 0 1 (1%) 1 (1%) 0
Progressive disease 26 (31%) 13 (62%) 126 (95%) 67 (96%) 59 (94%)
Treatment refused by patient 1 (1%) 1 (5%) 4 (3%) 0 4 (6%)
Patient died 10 (12%) 2 (10%) 0 0 0
Other 3 (4%) 3 (14%) 0 0 0
Best response to CT
Partial response 4 (5%) 0 11 (8%) 6 (9%) 5 (8%)
Stable disease 26 (31%) 10 (48%) 39 (29%) 18 (26%) 21 (33%)
Progressive disease 24 (29%) 11 (52%) 81 (61%) 46 (66%) 35 (56%)
Non-evaluable/not assessed 30 (36%) 0 2 (2%) 0 2 (3%)
  1. Abbreviations: CT=chemotherapy; SC=supportive care.